SCHEMBL667936

SCHEMBL667936

Cc1ccc(P(c2ccc(C)cc2)c2cc(C(C)(C)C)cc3c2Oc2ccc(C(C)(C)C)cc2C3(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.37
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667233 0.89 DRD1 (0.36) DRD1
SCHEMBL15685860 0.89 DRD1 (0.50) DRD1
SCHEMBL668454 0.87 ALDH1A1 (0.39) DRD1ALDH1A1MAPT
SCHEMBL29501652 0.85 DRD1 (0.55) DRD1TSHR
SCHEMBL21111854 0.85 DRD1 (0.55) DRD1TSHR
SCHEMBL29501658 0.85 DRD1 (0.55) DRD1TSHR
SCHEMBL15849058 0.80 ALDH1A1 (0.34) TSHRALDH1A1
SCHEMBL666909 0.80 DRD1 (0.65) DRD1
SCHEMBL667232 0.79 DRD1 (0.31) DRD1
SCHEMBL708320 0.78 DRD1 (0.61) DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912346-B2 Palladium phosphine complexes for the telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2014-12-16 US claimed
EP-2431375-B1 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2013-05-01 EP claimed
EP-2431375-A2 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2012-03-21 EP claimed
US-20120046475-A1 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2012-02-23 US claimed
US-8912346-B2 Palladium phosphine complexes for the telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2014-12-16 US disclosed
EP-2431375-B1 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2013-05-01 EP disclosed
EP-2431375-A2 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2012-03-21 EP disclosed
US-20120046475-A1 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046475-A1 PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE TTI1, TTI2, PAXBP1 DRD1 258/4885TSHR 1372/4885ALDH1A1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.